Nieuws en video's - RECURSION PHARMACEUTICALS INC.

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement Confirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatment Additional 4 patients demonstrated a best...

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized REC-1245 is a potent and selective RBM39 degrader with a potential first-in-class profile in Solid tumors and Lymphoma >100,000 patients in the US and EU5 initially addressable SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discovery Recursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and...

Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m....

SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16 , a publicly available foundation model in Google Cloud’s Vertex AI Model Garden . This will enable Life Science companies to use OpenPhenom-S/16 on Google Cloud when building apps that require microscopy data to assess the effectiveness of drug treatments, analyze cultures, study...

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39), which highlight a growing number of potential clinical program catalysts Our first neuroscience phenomap was optioned by Roche-Genentech for $30 million as part of a fee structure that could exceed a...

Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets. The company will not host its normal L(earnings) Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin's innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each year and more than 29,000 patients die in the U.S. from C. diff. annually. Rates of recurrent C. diff....

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, demonstrating a similar profile across placebo and both 200mg...

SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read: L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:30 am...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platform Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods Highly...

Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities Recursion expects 7 clinical trial readouts for itself over the next 18 months and approximately 10 clinical readouts collectively over the same time period as part of a combined company with Exscientia The first neuroscience phenomap under Recursion’s collaboration with Roche and Genentech has been optioned,...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and...

Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, following the close of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time, interacting with a broad public audience around notable...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to...

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion Recursion is a clinical stage TechBio company leading the...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. This proximity bias, discoverable through Recursion’s proprietary biological dataset, could have many...